Fulcrum Therapeutics, Inc. (FULC) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	—	—	80.0M	2.8M	6.3M
Cost of Revenue	14.6M	1.4M	63.4M	71.8M	76.8M
Gross Profit	(14.6M)	(1.4M)	16.6M	(69.0M)	(70.4M)
Operating Expenses
R&D Expense	56.2M	56.1M	63.4M	71.8M	76.8M
SG&A Expense	30.4M	28.7M	36.4M	41.7M	41.7M
General & Admin Expense	30.1M	28.7M	35.0M	39.2M	41.7M
Selling & Marketing Expense	260.0K	—	1.5M	2.5M	—
Other Expenses	(14.6M)	(1.4M)	(61.3M)	(71.8M)	(76.4M)
Total Operating Expenses	72.1M	83.4M	38.5M	41.7M	42.1M
Cost and Expenses	86.6M	84.8M	101.9M	113.5M	118.9M
Operating Income (EBIT)	(86.6M)	(84.8M)	(21.9M)	(110.7M)	(112.6M)
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	1.6M	9.9M	12.2M	13.3M	2.7M
Non-Operating Income (excl Interest)	(7.9M)	(9.9M)	(2.1M)	(13.3M)	(427.0K)
EBT (Pre-Tax Income)	(85.0M)	(74.9M)	(9.7M)	(97.3M)	(109.9M)
Income Tax Expense	—	—	—	—	—
Bottom Line
Net Income	(85.0M)	(74.9M)	(9.7M)	(97.3M)	(109.9M)
Earnings from Cont. Ops	(85.0M)	(74.9M)	(9.7M)	(97.3M)	(109.9M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(85.0M)	(74.9M)	(9.7M)	(97.3M)	(109.9M)
Per Share
Basic EPS	($1.21)	($1.18)	($0.16)	($1.59)	($2.35)
Diluted EPS	($1.21)	($1.18)	($0.16)	($1.59)	($2.35)
Revenue Per Share	$0.00	$0.00	$1.29	$0.05	$0.14
Shares
Basic Shares Outstanding	76.3M	63.4M	62.0M	61.3M	45.0M
Diluted Shares Outstanding	76.3M	63.4M	62.0M	61.3M	45.0M
Profitability Metrics
EBITDA	(77.5M)	(73.5M)	(18.2M)	(95.2M)	(109.7M)
D&A	1.2M	1.4M	1.6M	2.2M	2.4M
EBIT	(78.7M)	(74.9M)	(19.8M)	(97.3M)	(112.1M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026